IntroductIon
There is a worldwide epidemic of obesity, which is associated with a number of pathologies including dyslipidemia, glucose intolerance, insulin resistance and diabetes mellitus, all of which are risk factors for cardiovascular disease and mortality. [1] [2] [3] Diabetes is characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion and/or insulin action. The aim of therapy in diabetes is to achieve normoglycemia to prevent later microvascular complications (retinopathy, nephropathy, neuropathy and microangiopathy), and intensive therapy to achieve glycemic control has been shown to significantly diminish the risk of long-term complications. [4] Since lipid abnormalities, leading to premature atherosclerosis, are the major cause of cardiovascular diseases in diabetic patients, ideal treatment for diabetes, in addition to glycemic control, should have a favorable effect on lipid profile. The five types of oral anti-diabetic drugs, currently approved for the treatment of type 2 diabetes do not have a favorable effect on cardiovascular disease [5] , and some of these drugs are associated with serious adverse effects. Thus, new, relatively non-toxic, therapeutic agents are needed to treat hyperglycemia, which also would correct dyslipidemia to reduce the risk of cardiovascular complications of diabetes. Several FDA-approved drugs for conditions other than obesity have been investigated as treatment of excess body weight. [6, 7] Metformin is one such drug. Metformin, the biguanide most widely used for the treatment of type 2 diabetes mellitus [8] , may be useful in aiding weight loss. In diabetic patients, it suppresses endogenous glucose production and may also act as an Vol 1, Issue 1, Jan-Mar, 2011
Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation www.antiox.org insulin sensitizer. It also helps diabetic patients lose weight or at least keep their weight stable. [9] In recent years, polyphenols have been reported to possess various pharmacological actions, including anti-obesity [10, 11] , antidiabetic [12, 13] and anti-cancer. [14] Many plant extracts and plant products have been shown to have significant antiobesity and anti-diabetic activities, [15, 16] which may be an important property of medicinal plants associated with the treatment of several ill fated diseases including obesity, diabetes and atherosclerosis. Plant-derived polyphenols minimize obesity induced diabetes. [17] Among these herbal resources, the plant Jasonia montana occurs in the Mediterranean and adjacent areas, [18] including the Sinai Peninsula. [19] The herb has a strong aromatic odor and is used in traditional medicine for diarrhea, stomachache, and chest diseases. [20] Jasonia montana is one of the most common medicinal plants. The Jasonia montana owes its therapeutical activity to different groups of effective substances, which make up the complex effect of the drug. A literature survey indicated that some mono-and sesquiterpenes, [21] [22] [23] [24] flavonoids, [25] Essential oils are of greatest importance among all effective substances. [26] Poly-phenols exist in many plants and are especially abundant in Jasonia montana [27] , whose dried leaves are used as antioxidant. Jasonia montana and polyphenol-enriched plant extracts have no known toxicity. Thus polyphenols from Jasonia montana and possibly other plant sources represent a promising potential species. [28] These polyphenols are more potent antioxidants than vitamins C and E. [29] Polyphenol rich extracts from Jasonia montana inhibit lipid peroxidation in experimental animals. [28] [29] [30] Not surprisingly, plants such as Jasonia montana contain high levels of polyphenols, [29] which are excellent scavengers of reactive and represent a promising antiobesity effect. The different extracts of the plant were also tested for hypoglycemic, antidiabetic and anticholestatic activities. [28, 30] Recently, Hussein and Farghaly [31] studied the protective activity of Jasonia ethanolic extract against liver and kidney damage induced by iron-overloaded in adult rats and suggest that the aerial parts of J. montana extract may effectively normalize the impaired antioxidant status in iron-overloaded rats model experiment. In vivo tests have been conducted with Jasonia montana to determine, for example, its, hypoglycemic, [28] antioxidant, anticholestatic [30] and antihaemostatic [31] activities. But there are no reports of the anti-obesity effects of Jasonia montana in obese diabetic rats fed high-fat diet.
In continuation of my interested research program in the extraction and therapeutic evaluation of Jasonia montana extract [28, 30, 31] , I report herein, a facile route to explain the anti-obesity, antiatherogenic anti-diabetic and antioxidant effects of Jasonia montana extract in the form of ethanolic formulation in obese diabetic rats fed highfat diet, which may pave the way for possible therapeutic application.
MAtErIALS And MEtHodS

Plant material
Fresh aerial parts of J. montana were collected from the Sinai Peninsula.
Preparation of ethanolic extract
Air-dried aerial parts of the plant (1.5 kg) was crushed to coarse powder and extracted exhaustively in a Soxhlet with 95% ethanol. The extract was concentrated under reduced pressure to yield viscous mass. The ethanolic extract was kept in airtight containers in a deep freeze maintained at 4 o C until the time of further use.
Phytochemical screening
A phytochemical analysis of aerial parts of J. montana was conducted for the detection of alkaloids, cardiac glycosides, flavonoids, tannins, anthraquinones, saponins, volatile oil, coumarins and triterpenes. [32] 
Experimental set up
This experiment was carried out to examine the antiobesity and anti-diabetic affects of J. montana ethanolic extract in obese diabetic rats fed high-fat diet. Adult albino rats weighing around 150 ± 5 gms were purchased from Faculty of Veterinary Medicine, Cairo University. The animals were housed in individual cages with free access to water in a temperature-controlled facility with a 12:12-h light-dark cycle, and the animals were weighed periodically. During the acclimatization period, each animal was raised on a regular diet (Dyets Inc., Bethlehem, PA) ad libitum.
Ethanolic extract of J. montana air-dried aerial parts, given repeatedly for an 8-week period in vivo. A suspended solution of 3g % was prepared for intragastric intubation of rats. The animals were randomly divided into five groups 6 rats in each, two controls groups and three treatment groups.
Control group-I (was received a regular diet + 1 ml tween 80 for an 8-week period). Vol 1, Issue 1, Jan-Mar, 2011
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Control group-II (was received a high-fat diet + 1ml tween 80 for an 8-week period).
Group III: Was fed a high-fat diet with J. montana ethanolic extract (150 mg/kg bw/ml tween 80) suspended in tween 80 orally in a single daily dose for an 8-week period. [30] Group IV: Was fed a high-fat diet with J. montana ethanolic extract (300 mg/kg bw/ml tween 80) suspended in tween 80 orally in a single daily dose for an 8-week period. [30] Group V: Was fed a high-fat diet with metformin (500 mg/kg bw/ml tween 80) suspended in tween 80 orally in a single daily dose for an 8-week period. [33] Hyperglycemia induction diet was purchased from Dyets Inc. (AIN-76 diet #101772, Bethlehem, PA, USA). The nutrition contents of the high fat diet were similar to those of the regular diet except the addition of beef tallow (Table 1) . [34] Body weights were measured weekly, and every other week, blood was collected for blood glucose analysis. At the end of the study, blood was also collected for the determination of plasma insulin, insulin resistance index, atherogenic index and lipid levels. In addition, in vivo antioxidant and lipid peroxidation parameters in tissue of liver after which they were killed.
Blood sampling and plasma assay
Blood was withdrawn from the orbital venous plexus every other week, using a heparinized capillary tube without anesthesia. The blood samples were placed on ice, centrifuged, and plasma stored at -20 o C until assayed. The plasma glucose concentration was determined using the glucose oxidase method (Youngdong Pharmaceutical Co, Korea). The plasma insulin concentration was measured according to the protocol described by the manufacturer of the insulin ELISA kit (Shibayagi Co., Japan). The insulin resistance index, calculated by insulin (mU/ml) X glucose (mM)/22.5 (35) . Plasma triglyceride, total cholesterol, HDL-cholesterol and free fatty acid concentrations were determined using commercially available kits (Asan and Youngdong Pharmaceutical Co., Korea). Plasma LDL-cholesterol level was calculated from Friedewald [36] formula (LDLcholesterol = total cholesterol -triglycerides/5 -HDLcholesterol). Plasma vLDL-cholesterol concentration was calculated according to Nobert (47) formula (vLDL-cholesterol = triglycerides/5). The atherogenic index [log (TG/ HDL-C)] was also calculated. [37] On the other hand, liver triglyceride and cholesterol content were measured as described previously. [38, 39] Briefly, a portion (100 mg) of liver tissue was homogenized in phosphate buffer saline (pH 7.4, 1 ml). The homogenate (0.2 ml) was extracted with isopropyl alcohol (1 ml), and the extract was analyzed using a Triglyceride E-Test (Wako Pure Chemical Industries) to determine liver triglyceride content. The homogenate (0.2 ml) was extracted with chloroformmethanol (2: 1, 1 ml), and the extract was concentrated under a nitrogen stream. The residue was dissolved in isopropyl alcohol and analyzed using a Cholesterol E-Test (Wako Pure Chemical Industries). Finally, another portion from liver was blotted, weighed and homogenized with methanol (3 volumes). The lipid extract obtained by the method of Folch et al. [40] It was used for the estimation of thiobarbituric acid reactive substances (TBARS). [41] Another portion of the tissues was homogenized with phosphate buffer saline and used for the estimation of reduced Glutathione (GSH), [42] Glutathione peroxidase (GPx) [43] , Glutathione reductase (GR) [44] , Superoxide dismutase (SOD) [45] and Catalase (CAT).
[46]
Statistical analysis
The data were analyzed using the one-way analysis of variance (ANOVA) [47] followed by least significant difference (LSD) test to compare various groups with each other. Results were expressed as mean ± standard Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation
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shown in Table 3 , weight gain of the high fat diet control rats was actually due to the increased food intake. However, body weights of J. montana extract fed rats were significantly reduced despite the even larger increase in food intake compared to the high fat diet control rats. Feed efficiency of the J. montana ethanolic extract (300 mg/kg) fed group was 1.9, which is lower than the value shown for the high fat diet control group and similar to that of regular diet fed group mainly due to a significant reduction of food intake compared to the high fat diet control group, indicating that J. montana extract could be a fascinating drug that allows patients to slim down despite an increase in food intake or reduction of physical activity. On the other hand, body weight of metformin fed group was near to that of regular diet fed group mainly due to a significant reduction of food intake compared to the high fat diet control group.
Insulin resistance index (IRI)
Plasma glucose was determined every other week and was compared between groups in table 4. Plasma glucose levels were barely increased in the regular diet fed control group, while a marked increase after the 8 weeks was observed for rats only fed with the high fat diet. J. montana ethanolic extract fed rats, however, showed a significant decrease in blood glucose levels in a dose dependent manner when compared to the high fat diet control group error (SE) and values of P>0.05 were considered nonsignificantly different, while those of P<0.05 and P<0.01 were considered significant and highly significant, respectively. F-probability expresses the general effect between groups. The means that were not significantly different are followed by the same superscript symbol(s).
rESuLtS
Body weight and food intake were determined once every 2 weeks. The body weight of the normal rats in the regular diet group gradually increased as the rats grew during the 8-week trial. In contrast, the body weight of animals on the high fat diet showed rapid increases during the course of the trial ( Table 2 ). Weight gains in regular diet and high fat diet control groups during the 8-week period were 17.7±2.4g and 56.8±4.1g, respectively (Table 3) . Subjects fed the high fat diet and J. montana ethanolic extract showed a gradual increase in body weight, but the increase was significantly less than that detected for the high fat diet control group in spite of continued and prolonged access to the high fat diet (Table 2) . J. montana 150 and 300 mg/kg bw prevented the weight gain by 31.19 % and 48.96 %, respectively, compared to the body weight of the high fat diet control group. Feed efficiency, calculated by weight gain divided by total food intake during the 8-week period, was compared in order to figure out the relationship between food intake and weight gain. As Body weight of rats consuming regular diet, high fat diet, high fat diet plus J. montana ethanolic extract or fed with high fat diet plus 500 mg/kg of metformin during the 8-week period. Values are given as mean ± SD for groups of six animals each. High-fat diet control rats were compared with regular diet control rats. Experimental groups were compared with the high-fat diet control rats. Vol 1, Issue 1, Jan-Mar, 2011
www.antiox.org Values represent the mean ± SE (n=6). High-fat diet (HFD) control rats were compared with regular diet (RD) control rats. Experimental groups were compared with the high-fat diet control rats. Insulin Resistance Index = insulin (mU/ml) x glucose (mM) / 22.5.
( Table 4 ). Plasma insulin levels in J. montana 150 and 300 mg/kg bw treated groups were also markedly decreased by 34.62% and 38.25%, respectively when compared to the high fat diet control group (Table 4) . Also, plasma glucose levels in J. montana 150 and 300 mg/kg bw treated groups were also markedly decreased by 33.19% and 40.65%, respectively when compared to the high fat diet control group (Table 4) . The insulin resistance index, calculated by [insulin (mU/ml) X glucose (mM)]/22.5, of the high fat diet control group was 3.5 times higher than that of the regular diet group, while insulin resistance indices of J. montana 150 and 300 mg/kg bw were Vol 1, Issue 1, Jan-Mar, 2011
Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation www.antiox.org 31 .18%, 52.33%, 20.32% and 29.09%, while they showed an increased level of HDL-C by 81.02% with compared to that in high fat diet fed control group. On the other hand, J. montana 300 mg/kg bw-treated group, however, showed considerably reduced levels of TG, TC, LDL-C, v LDL-C and free fatty acid by 35.03%, 42.73%, 67.20%, 35.02% and 99.93%, while they showed an increased level of HDL-C by 91.63% with compared to that in high fat diet fed control group. The atherogenic index, calculated by log (TG/HDL-C), of the high fat diet control group was 6.93 times higher than that of the regular diet group, while atherogenic index of J. montana 150 and 300 mg/ kg bw were significantly reduced by 53.98% and 70.68%, respectively, when compared to the high fat diet control group (Table 5 ). Metformin remarkably improved high fat diet induced dyslipidemia, and all lipid related plasma parameters in metformin fed rats were comparable to those in regular diet fed rats. Table 6 shows liver lipid content. At the end of administration, liver triglyceride and cholesterol levels were significantly higher for the high fat diet fed group when compared to the regular fed group. For high fat diet/J. montana 150 and 300 mg/kg bw groups, triglyceride and cholesterol accumulation were significantly significantly reduced by 56.33% and 63.36%, respectively, when compared to the high fat diet control group (Table 4) . Improvement of insulin resistance in the J. montana ethanolic extract (300 mg/kg bw) fed group was significant and comparable to the metformin (500 mg/kg bw) fed group. This result suggests that wild J. montana extract was able to lower the blood glucose level partially due to the improvement of insulin resistance.
Liver triglyceride and cholesterol content
Plasma lipid levels
The effects of J. montana ethanolic extract on plasma lipid levels were examined at the end of the treatment. The plasma lipid levels in high fat diet fed rats were dramatically increased compared to the levels in regular diet fed rats except for the HDL-cholesterol (HDL-C) level, which is supposed to be higher than 40 mg/dl (Table 5 ). In the high fat diet control group, plasma triglyceride (TG) was increased by 1.69-fold (115 to 195 mg/dl), total cholesterol was increased by 2.15-fold, LDL-cholesterol increased by 6.78-fold, vLDL-cholesterol increased by 1.69-fold, free fatty acid increased by 1.94-fold, and total cholesterol (TC) increased as reflected in the increase in LDLcholesterol (LDL-C) concentration compared to those in the regular diet group. J. montana 150 mg/kg bw-treated group, however, showed considerably reduced levels of TG, TC, LDL-C, v LDL-C and free fatty acid by 20.32%, Table 5 . Effect of J. montana ethanolic extract on plasma triglyceride (TG), total Cholesterol (TC), HDLcholesterol (HDL-C), LDL-cholesterol (LDLC), vLDL-cholesterol (vLDLC), nonesterified fatty acid (NEFA) and atherogenic index. Values represent the mean ± SE (n=6). High-fat diet (HFD) control rats were compared with regular diet (RD) control rats. Experimental groups were compared with the high-fat diet control rats. www.antiox.org and 42.21%, respectively when compared to the high fat diet control group (Table 6) . Liver thiobarbituric acid reactive substances (TBARS), reduced Glutathione (GSH), Glutathione peroxidase (GPx), Glutathione reductase (GR), Superoxide dismutase (SOD) and Catalase (CAT) content. Tables 7 and 8 shows liver TBARS, GSH, GPx, GR, SOD and CAT content. At the end of administration, liver TBARS level was significantly higher for the high fat diet fed group when compared to the regular fed group. For both high fat diet/J. montana 150 and 300 mg/kg bw groups TBARS accumulation was significantly suppressed. Liver TBARS level in J. montana 150 and 300 mg/kg bw treated groups were markedly decreased by 44.03% and 55.96%, respectively when compared to the high fat diet control group (Table 7) . Also, liver GSH, GPx, GR, SOD and CAT were significantly lower for the high fat diet fed group when compared to the regular fed group (Tables  7&8) . Liver GSH level in J. montana 150 and 300 mg/kg bw treated groups were markedly increased by 91.42 % and 142.85%, respectively when compared to the high fat diet control group (Table 7) . Liver GPx level in J. montana 150 and 300 mg/kg bw treated groups were markedly increased by 47.28% and 77.11%, respectively when compared to the high fat diet control group (Table 7) . On the other hand, Liver GR level in J. montana 150 and 300 mg/kg bw treated groups were markedly increased by 55.29% and 120%, respectively when compared to the Values represent the mean ± SE (n=6). High-fat diet (HFD) control rats were compared with regular diet (RD) control rats. Experimental groups were compared with the high-fat diet control rats. Values represent the mean ± SE (n=6). High-fat diet (HFD) control rats were compared with regular diet (RD) control rats. Experimental groups were compared with the high-fat diet control rats.
suppressed. Liver triglyceride levels in J. montana 150 and 300 mg/kg bw treated groups were markedly decreased by 47.68% and 55.16%, respectively when compared to the high fat diet control group (Table 6 ). Liver total cholesterol levels in J. montana 150 and 300 mg/kg bw treated groups were also markedly decreased by 32.55% Vol 1, Issue 1, Jan-Mar, 2011
Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation www.antiox.org obesity and diabetes. [52] In the present study, high-fat diet was administered to 8-week-old to induce severe obesity and diabetes and the effects of J. montana ethanolic extract were evaluated. High-fat diet is widely used in studies on obesity and diabetes. [53] J. montana was found to significantly suppress increases in body weight, showing anti-obesity actions (Table 2) . Plasma glucose and insulin levels were significantly higher for the high-fat diet group than for the regular diet group, and severe type II diabetes was induced. J. montana suppressed these increases in plasma glucose and insulin levels. The insulin resistance index, a simpler method to measure insulin sensitivity usually used in clinical and animal studies, [54] was significantly decreased in J. montana -treated groups compared to the high-fat diet group, indicating that J. montana reduced hyperglycemia [28] and hyperinsulinemia (Table 4 ). These findings clarify that J. montana suppresses obesity and diabetes caused by a high-fat diet. Obesity is caused by low energy expenditure and increased fatty acid synthesis from carbohydrates and fat intake by organs. J. montana ethanolic extract was found to significantly suppress increases in plasma lipids content, showing anti-obesity actions (Table 5) . High-fat diet also increased liver fat accumulation and induced fatty liver, but J. montana administration lowered fat accumulation, clarifying that J. montana ethanolic extract suppresses TG, TC, HDL-C, LDL-C, vLDL-C and free fatty acid ( Table 5 ). The elevation of TG, TC, LDL-C, v LDL-C and free fatty acid up on high fat diet feeding is not surprising and is in agreement with several studies. [30] The high fat diet control group (Table 7 ). In addition, Liver SOD level in J. montana 150 and 300 mg/kg bw treated groups were markedly increased by 82.95% and 129.55%, respectively when compared to the high fat diet control group (Table 8 ). Finally, Liver CAT level in J. montana 150 and 300 mg/kg bw treated groups were markedly increased by 30.70% and 64.31%, respectively when compared to the high fat diet control group (Table 8) .
dIScuSSIon
Obesity is the most common nutritional disorder in the developed world and it is considered a risk factor associated with the development of major human diseases, including cardiovascular disease, diabetes, and cancer. A daily consumption of diets high in fat tends to promote obesity. Increased intake of high caloric (energy and fat) food promotes body fat storage and greater body weight and adiposity in humans [48] and animals. [49] Over-the-counter remedies based on nutritional supplements are extremely popular, especially with respect to obesity and body composition. Inhibition of the digestion and absorption of dietary fat has been used as targets in obesity treatment. [50] The anti-obesity effects of J. montana ethanolic extract was investigated using obese diabetic rats fed high-fat diet as a model of obese type-II diabetes. When fed a high-fat diet, rats develop obesity and type-II diabetes by 12-weeks old, [51] and these rats are thus widely used for research into Values represent the mean ± SE (n=6). High-fat diet (HFD) control rats were compared with regular diet (RD) control rats. Experimental groups were compared with the high-fat diet control rats. Vol 1, Issue 1, Jan-Mar, 2011
www.antiox.org quercetin has been reported to lower hepatic and blood cholesterol levels, as stated by Park et al. [61] . Taken together, it can be concluded that the ameliorative effect of J. montana extract on plasma lipids variables may be attributed to their insulin releasing capacity and insulin binding affinity and decreasing intestinal cholesterol absorption and activity of hepatic HMG-CoA reductase. In the third mechanism, amelioration of the glycemic, lipidemic and antioxidant states of diabetic rats in response to treatment with J. montana flavonoids may also be attributed to the increased expression of PPARγ. The effect of PPARγ on lipid and glucose control may be explained according to Lee et al . [62] , Staels and Fruchart [63] , Feige et al. [64] and Lefebvre et al. [65] , who state that PPARγ promotes preadipocyte differentiation, stimulates the storage of fatty acids (FAs) in adipocytes and enhances insulin sensitivity. The action of PPARγ on insulin sensitivity results from its ability to channel FAs into adipose tissue, thus decreasing plasma FA concentration and alleviating lipotoxicity in skeletal muscle, liver and pancreas. Also, PPARγ activation has been reported to improve insulin resistance by lowering the hepatic triglyceride content [66, 67] , activating hepatic glucokinase expression [68] and exhibiting an antiatherogenic effect synergistic with an HMG-CoA reductase inhibitory effect in rabbits. [69] In addition, PPARγ can affect insulin sensitivity by regulating adipocyte hormones, cytokines and proteins that are involved in insulin resistance. Indeed, PPARγ down regulates the expression of genes encoding resistin and TNFα, whereas it induces adiponectin expression, which increases FA oxidation by activation of the AMP-activated protein kinase pathway. [70, 71] Also , Willson et al. [72] demonstrated the activation of PPARγ to improve insulin sensitivity and lower circulating levels of glucose, triglycerides and FFAs without stimulating insulin secretion in rodent models of type 2 diabetes. Jung et al. [60] , who found an increased expression of PPARγ by the flavonoids and that of Anandharajan et al. [70] , who showed an increased PPARγ expression by Pterocarpus marsupium isoflavone on L6 myoblasts and myotubes. Moreover, Hussein and AbdelGawad [30] reported that the J. montana ethanolic extract decrease serum TNFα level in rats with liver cholestasis induced by ethinylestradiol. The presence of these compounds in J. montana ethanolic extract play a role in the observed hypocholesterolemic effects (Tables 5 and  6 ). These compounds may influence glucose metabolism by several mechanisms, such as inhibition of carbohydrate digestion and glucose absorption in the intestine, stimulation of insulin secretion from the pancreatic β-cell, modulation of glucose release from liver, activation of results showed that upon administration J. montana ethanolic extract for 8 weeks significantly decreased the plasma TG, TC, LDL-C, vLDL-C, and free fatty acid (Table 5) . Most of the reduction in plasma cholesterol occurred in the fraction of LDL. Because of apo B containing lipoprotein fractions are through to be responsible for cholesterol deposition in atherosclerotic plaques, [55] a reduction in LDL would be advantageous clinically extract had an improving effect on the hypercholesterolemia induced by a high fat diet. J. montana treated animals also showed a decrease in the atherogenic index with hypercholesterolemic groups (Table 5) , which is generally believed to be beneficial since the HDL level inversely correlated heart disease and reduction in this ratio is considered as an anti-atherosclerotic factor. Not surprisingly, plants such as Jasonia montana contain high amount of polyphenols [28] , mono-and sesquiterpenes [21] [22] [23] [24] , Essential oils and flavonoids [25] ; 3,6,7,3`,4`-pentamethoxy quercetin (artemitin), 3,6,7,3`-tetramethoxy quercetin (chrysosplenetin), 3,6,3`,4`-tetramethoxy quercetin, 3,6,7-trimethoxy kaempferol, 3,6,3`-trimethoxy quercetin (jaceidin), 3,6,4`-trimethoxy quercetin (centaureidin), 3,3`,4`-trimethoxy quercetin, 3,6-dimethoxy quercetin, 3,3`-dimethoxy quercetin, 7,4`-dimethoxy quercetin, quercetin, quercetin-3-O-â-D-4C1-glucopyranoside, 3,5-dicaffeoyl-quinic acid, caffeic acid, quercetin-3-O-L-1C4-rhamnopyranoside (Quercitrin) and quercetin-3-O-â-D-4C1 glucuronopyranoside [56] which are excellent hypocholesterolemic effect. The ability of quercetin to reduce plasma lipids in diabetic animals could be explained by the insulin releasing capacity of quercetin in isolated rat islets of Langerhans. [57] The reduction of plasma lipids (Table 5 ) and liver cholesterol and triglycerides (Table 6) might have a role in the mechanism of action to augment the hypolipidemic activity of the J. montana ethanolic extract containing flavonoids, especially quercetin derivatives. This assumption is supported by three mechanisms; the first is indicated that J. montana extract successfully decreased the intestinal cholesterol absorption in situ. [58] The second mechanism indicated that the hypolipidemic activity of J. montana flavonoids treatments may also be mediated via inactivation of hepatic HMGCoA reductase, a key enzyme, in cholesterol synthesis. In concurrence with this attribution, Raz et al. [59] state that inhibitors of hepatic HMG-CoA reductase are well established drugs for the treatment of hypercholesterolemia and decrease the incidence of dyslipidemia in diabetic subjects. This also coincides well with the work of Jung et al. [60] , who state that flavonoids decrease liver HMGCoA reductase activity in type 2 diabetic mice. Moreover, Vol 1, Issue 1, Jan-Mar, 2011
Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation www.antiox.org insulin receptors and glucose uptake in the insulinsensitive tissues, and modulation of hepatic glucose output. My study suggests that J. montana ethanolic extract containing polyphenols may act on liver to increase energy expenditure related fatty liver degradation. Furthermore, J. montana polyphenols may decrease mRNA expression of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS)], the rate-limiting enzymes of fatty acid synthesis in the liver, and mRNA expression of [sterol regulatory element-binding protein (SREBP)-1c [73] , which controls the expression of these enzymes. [74] These findings indicate that the anti-obesity actions of J. montana ethanolic extract are may due to increased expression of energy expenditure-related genes in liver and decreased fatty acid synthesis and fat intake in the liver. On the other hand, Insulin resistance can be generated by decreased adiponectin secretion and decreased TNF-α secretion. [75, 76, 30] Tables 7 and 8 illustrate the activities of liver TBARS, GSH, GPx, GR, SOD and CAT. TBARS levels were increased in liver in group II rats are a clear manifestation of excessive formation of free radical and activation of lipid peroxidation. The significantly reduced the levels of TBARS, in rats administered with J. montana ethanolic extract along with HFD. Glutathione, an endogenous antioxidant defense, is found in liver at high concentration. It plays a central role in the defense against free radicals, peroxides and a wide range of xenobiotics and carcinogens. [77] Table 7 and 8 demonstrates the levels of oxidative stress biomarkers; GSH, GPx, GR, SOD and CAT in HFD rats. The significant fall in the levels of tissues oxidative stress biomarkers were observed in high fat diet rats (Group II) as compared to the control rats (Group I). Administration of ethanolic extract of J. montana along with HFD rats substantially enhanced the levels of these enzymes when compared with HFD rats (Group II). Not surprisingly, plants such as Jasonia montana contain high amount of polyphenols [28] , mono-and sesquiterpenes [21] [22] [23] [24] , Essential oils, flavonoids [25] and other tri-tetra and tetraquercetin derivatives [56] which are excellent antioxidant effect. My results also coincides with Hussein [29] , Hussein and Abdel-Gawad [30] and Hussein and Farghaly [31] who proved that the antioxidant activity of J. montana ethanolic extract using different mechanisms. Various pharmacological actions of J. montana have been reported. The J. montana used in the present study acted on fatty liver and was shown to possess anti-obesity and anti-diabetic actions. While many studies have described plant extracts exhibiting antioxidant and anti-diabetic actions, to the best of our knowledge, none have demonstrated anti-obesity and anti-diabetic actions via reduction of insulin resistance and atherogenic index. The preliminary phytochemical screening of J. montana revealed the presence of flavonoids. Flavonoids (or bioflavonoids) are natural products that are capable of modulating of insulin resistance and atherogenic index. Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation in Obese diabetic rats fed high-fat diet has not been reported earlier to my knowledge, and this study is might be the first observation of that kind.
In conclusion, the present study showed that the effects of Anti-obesity, antiatherogenic, anti-diabetic and antioxidative activities of J. montana depend on the presence of a high amount of polyphenols, mono-and sesquiterpenes, Essential oils, flavonoids and other di, tri and tetraquercetin derivatives in J. montana ethanolic extract.
rEfErEncES
